A Need for Alignment: How ICER's New Cost-Effectiveness Framework Compares with the Second Panel's Recommendations
Methodologists in the HEOR community have been busy over the past 9 months. In September 2016, the Second Panel on Cost-Effectiveness in Health and Medicine published a special communication in JAMA (and subsequent hardcover book) that sought to provide guidance for improving the quality of cost-effectiveness (CE) analyses. A few months later in[…]
How Does ICER’s Incremental Cost-Effectiveness Analysis Stack Up to Industry Practice?
In early February, the Institute for Clinical and Economic Review (ICER) presented proposed updates to its Value Assessment Framework, based largely on stakeholder feedback received during a public comment period in late 2016. These updates focused on four domains of the framework: (1) comparative clinical effectiveness; (2) incremental[…]
Big Changes for HEOR in 2017
As we make our way through the first quarter of 2017, there are a lot of exciting changes happening in the field of health economics and outcomes research (HEOR) that may have important implications for how researchers generate and disseminate evidence.
ICER's New Cost-Effectiveness Threshold Raises 5 Major Questions
Early last month the Institute for Clinical and Economic Review (ICER) released a revised Value Assessment Framework for public comment based on feedback received from patients, clinicians, life science companies, and other stakeholders. While a majority of the proposed changes lacked real luster, there is one proposed change that pharma should[…]
2016 Industry Insights: RWE and Centers of Excellence (CoE) Teams Growing
At BHE, we spend a lot of time speaking with leaders in the field of real world data about the ways in which they go about generating robust, reliable evidence for use with key stakeholders both internally and externally. Fundamentally, the unique way that companies combine database experts, processes, and technology provides the best indication[…]